KPV: The Honest Guide to an Ingredient You Cannot Buy on Its Own

Section 01

What KPV Actually Is

KPV is a tripeptide. Three amino acids: lysine, proline, valine. The name is simply their one-letter codes, K-P-V. It is not a synthetic invention so much as a fragment of something your body already produces: it is the C-terminal tail of alpha-melanocyte-stimulating hormone, written in the literature as alpha-MSH(11-13).

Alpha-MSH is a thirteen-amino-acid hormone with two well-described roles: it drives pigmentation through the melanocortin receptors, and it dampens inflammatory signalling. The interesting observation behind KPV is that those two functions appear to separate. In laboratory models the three-amino-acid tail retains a good deal of the anti-inflammatory activity while no longer binding the melanocortin receptors responsible for pigment. That is the whole rationale for using the fragment instead of the hormone.

KPV is not an FDA-approved drug, and it is small enough to be worth saying plainly: at three amino acids it sits at the very bottom of the size range people mean by “peptide”, and its small size is part of why it is being investigated for oral and colon-targeted delivery.

Section 02

Why You Cannot Buy KPV on Its Own

RxPepsDirect does not dispense KPV as a standalone product. There is no KPV-only vial and no KPV-only capsule. It reaches patients only as one ingredient inside a combination, and there are three of them.

The practical difference between the two injectables is copper. KLOW adds GHK-Cu, a copper-carrying tripeptide, and the three-peptide vial deliberately leaves it out. If copper is a concern, whether because of a copper-handling condition or simple preference, the no-copper vial is the one to discuss with your prescriber. Between the injectable and the capsule the difference is route rather than formula philosophy.

Section 03

How It Is Proposed To Work

The mechanism most often cited for KPV is suppression of NF-kB signalling. NF-kB is a transcription factor that sits near the top of the inflammatory cascade: when it is activated it switches on a large set of genes that produce inflammatory cytokines. A compound that dampens NF-kB activity would, in principle, reduce inflammatory output broadly rather than blocking one specific mediator.

In cell and animal work KPV appears to act inside the cell rather than at a surface receptor, and at least one of the colitis studies found effects that persisted in animals lacking the MC1R melanocortin receptor, which is part of why the fragment is thought to work through a different route than the parent hormone’s pigment pathway.

Section 04

What the Evidence Actually Shows

The KPV literature is small, genuinely interesting, and entirely preclinical. It clusters around gut inflammation.

Two things follow from that table. First, the strongest KPV data is in the gut, which is why it turns up in gut-focused protocols and in an oral capsule alongside BPC-157. Second, and more important, the gap between a mouse colitis model and a person taking a compounded capsule is very large. Dose, route, delivery and species all differ, and the Laroui result in particular depended on targeting the compound directly to the colon.

Section 05

Why KPV Has No Dose of Its Own

“KPV dosage” is one of the most common searches about this molecule, and the honest answer is that the question does not have a standalone answer here. Your KPV dose is a consequence of which combination you were prescribed and how much of it you draw.

Your prescription label and your prescriber’s directions control your dose. No clinically validated KPV dose exists to check it against.

Section 06

Safety and Screening

There is no human safety dataset for KPV. That is not the same as saying it is dangerous; it means the honest position is uncertainty rather than reassurance. Reported tolerability comes from clinic observation and patient report, not from controlled study.

Because KPV is only dispensed inside a combination, the screening that matters is the screening for the product you are actually prescribed, and those products carry more established concerns than KPV does on its own. Discuss with your prescriber: autoimmune conditions, cancer history or active malignancy, pregnancy or breastfeeding, current medications and supplements, and, for KLOW specifically, copper-handling disorders such as Wilson’s disease and copper sensitivity.

Section 07

Regulatory Status

KPV is not an FDA-approved drug and has no approved labelling. That makes its use here unapproved rather than off-label, which is a distinction worth keeping straight: off-label describes an approved drug used outside its approved labelling, and there is no label here to be outside of.

In July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding KPV, alongside BPC-157 and TB-500, to the 503A Bulks List. That vote is a recommendation. It is advisory and nonbinding, and it does not by itself create FDA approval or final placement on the list. Anyone presenting it as an approval is overstating it.

Section 08

Community Q&A

Section 09

The RxPepsDirect Model